6533b858fe1ef96bd12b6345

RESEARCH PRODUCT

The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk

Pugliese NrMengozzi AVirdis ACasiglia ETikhonoff VCicero AfgUngar ARivasi GSalvetti MBarbagallo CmBombelli MDell'oro RBruno BLippa LD'elia LVerdecchia PMallamaci FCirillo MRattazzi MCirillo PGesualdo LMazza AGiannattasio CMaloberti AVolpe MTocci GGeorgiopoulos GIaccarino GNazzaro PParati GPalatini PGalletti FFerri CDesideri GViazzi FPontremoli RMuiesan MlGrassi GMasi SBorghi CWorking Group On Uric Acid And Cardiovascular Risk Of The Italian Society Of HypertensionCicero Afg

subject

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaCardiovascular mortalityPrognosiSudden cardiac deathchemistry.chemical_compoundSerum uric acidRisk FactorsInternal medicineCause of DeathmedicineHumansSerum uric acid.Myocardial infarctionCardiovascular mortality; Metabolic syndrome; Prognosis; Serum uric acidStrokeRetrospective StudiesOriginal Paperbusiness.industryProportional hazards modelHazard ratioGeneral MedicineMiddle Agedmedicine.diseasePrognosisMetabolic syndromeUric AcidSurvival RatechemistryItalyCardiovascular DiseasesHeart failureCardiologyUric acidFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up Studies

description

Abstract Introduction Serum uric acid (SUA) has been depicted as a contributory causal factor in metabolic syndrome (MS), which in turn, portends unfavourable prognosis. Aim We assessed the prognostic role of SUA in patients with and without MS. Methods We used data from the multicentre Uric Acid Right for Heart Health study and considered cardiovascular mortality (CVM) as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart failure. Results A total of 9589 subjects (median age 58.5 years, 45% males) were included in the analysis, and 5100 (53%) patients had a final diagnosis of MS. After a median follow-up of 142 months, we observed 558 events. Using a previously validated cardiovascular SUA cut-off to predict CVM (> 5.1 mg/dL in women and 5.6 mg/dL in men), elevated SUA levels were significantly associated to a worse outcome in patients with and without MS (all p < 0.0001) and provided a significant net reclassification improvement of 7.1% over the diagnosis of MS for CVM (p = 0.004). Cox regression analyses identified an independent association between SUA and CVM (Hazard Ratio: 1.79 [95% CI, 1.15–2.79]; p < 0.0001) after the adjustment for MS, its single components and renal function. Three specific combinations of the MS components were associated with higher CVM when increasing SUA levels were reported, and systemic hypertension was the only individual component ever-present (all p < 0.0001). Conclusion Increasing SUA levels are associated with a higher CVM risk irrespective of the presence of MS: a cardiovascular SUA threshold may improve risk stratification. Graphic abstract

yearjournalcountryeditionlanguage
2021-01-01
10.1007/s00392-021-01815-0http://hdl.handle.net/11577/3392959